Weight Loss Drugs May Be Linked to Bone Health Risks, Five-Year Study Shows

Key Takeaways:

• A large observational study suggests a modest increase in osteoporosis and related conditions among people taking GLP-1 receptor agonists over five years
  
• The underlying cause remains unclear, with weight loss itself, rather than the drugs alone, likely contributing to changes in bone health
  
• Despite these findings, the cardiovascular and metabolic benefits of GLP-1 therapies continue to outweigh potential skeletal risks for most people
  
  
  

Growing use of GLP-1 therapies raises new questions

Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1 drugs, are widely used to manage type 2 diabetes and support weight loss. These medications are recognised for their ability to reduce body weight, improve glycaemic control, and lower cardiovascular risk.

However, emerging long-term data are beginning to highlight potential concerns relating to bone health. A new study, presented at the 2026 annual meeting of the American Academy of Orthopaedic Surgeons, examined five years of real-world data and suggests that these treatments may be associated with an increased risk of certain skeletal conditions.

The findings are observational and have not yet undergone peer review. They demonstrate association rather than causation. Nevertheless, given the rapid uptake of GLP-1 receptor agonists, researchers emphasise the need for careful, ongoing evaluation.

Study findings – signals of increased skeletal risk

Researchers analysed medical records from more than 146,000 adults living with obesity and type 2 diabetes over a five-year period.

Among those taking GLP-1 therapies, approximately 4 percent developed osteoporosis, compared with just over 3 percent of those not taking these medications.

Additional findings included:

• Osteomalacia, or bone softening, occurred in around 0.2 percent of people using GLP-1 drugs, compared with 0.1 percent in the control group
  
• Gout was slightly more common, affecting 7.4 percent of people taking GLP-1 therapies compared with 6.6 percent in those not taking them
  

Lead researcher Muaaz Wajahath, a medical student at Michigan State University College of Human Medicine, highlighted the importance of emerging long-term data:

“We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” Wajahath said. “Any medication that sees this rapid adoption warrants close examination, particularly in orthopedics, where obesity and surgical intervention often overlap.”

Dr Giles Scuderi, an orthopaedic surgeon and vice president of Northwell Orthopedics, commented on the findings:

“The study findings contradict recent assertions of musculoskeletal protection and suggest that GLP-1 RA exposure may confer increased long-term skeletal risk.”

Is the risk driven by the drug or by weight loss?

A key question remains whether the observed risks are directly caused by GLP-1 medications or are instead related to weight loss itself.

People living with obesity and type 2 diabetes already have elevated risks of inflammation and bone fragility. In addition, weight loss – particularly when rapid or substantial – can affect bone metabolism.

Dr James J. Chao explained:

“As with any weight loss, bone remodeling can occur if patients lose weight on these medications.”

Bone remodelling is the continuous process of breaking down old bone and replacing it with new tissue. During periods of calorie deficit, this balance can shift, resulting in net bone loss.

“If patients lose lean mass on these medications, bone health can be affected due to less strain being placed on bones,” he added.

Dr Fernando Ovalle Jr. reinforced that this is not unique to GLP-1 therapies:

“We’ve seen it with bariatric surgery for many years and even with aggressive caloric restriction. That’s not unique to GLP-1s.”

Balancing risks and benefits

Despite these findings, experts continue to support the use of GLP-1 receptor agonists in appropriate patients.

These medications have demonstrated strong benefits, including:

• Improved glycaemic control
• Reductions in blood pressure and lipid levels
• Lower risk of heart attack and stroke
  

“In high-risk patients, those benefits are substantial and often life-saving,” Ovalle said.

As a result, the overall benefit–risk balance remains favourable in most cases. While there may be a modest increase in fracture or gout risk, these risks can typically be monitored and managed.

Scuderi echoed this perspective:

“Since heart disease is a leading cause of death, the potential risk of muscle and bone problems might be less important.”

He also emphasised the importance of active clinical management rather than passive prescribing.

Practical steps to protect bone health

Healthcare professionals can take a proactive role in supporting people receiving GLP-1 therapies.

Recommended strategies include:

• Ensuring adequate protein intake to support muscle mass
• Maintaining sufficient calcium and vitamin D levels
• Engaging in regular resistance and weight-bearing exercise
• Avoiding excessively rapid or unsupported weight loss

“Strength training, in particular, is critical,” Ovalle said. “Preserving muscle mass protects bone. If a patient loses weight but also loses significant muscle, fracture risk can increase regardless of the medication used.”

Certain groups may require closer monitoring:

• Postmenopausal women
• Older adults
• Individuals with a history of fractures
  

Gout risk may also increase temporarily during periods of rapid weight loss.

“Regarding gout, rapid weight loss and changes in uric acid metabolism can transiently increase flares,” Ovalle said. “That’s something we’ve seen even outside of GLP-1 therapy.”

For individuals concerned about bone health, targeted supplementation may be considered. Scuderi noted that healthcare professionals may recommend therapeutic doses of dietary supplements to support lean mass retention and reduce inflammation.

A signal worth monitoring, not a cause for alarm

While early long-term data suggest a potential association between GLP-1 therapies and bone-related risks, these findings should be interpreted with caution.

The study does not establish causation, and multiple factors – including weight loss, underlying conditions, and changes in body composition – are likely to contribute.

At present, GLP-1 receptor agonists remain a valuable and often transformative option for people living with obesity and type 2 diabetes, provided their use is accompanied by appropriate clinical oversight and supportive lifestyle measures.

CCH insight

With so many people taking GLP-1 medications, it is important to keep researching the long-term effects, and this study sheds important light on potential risks with regard to bone health. The most important message here, however, is that this reminds us how it is vital that patients on GLP-1 therapy need to be carefully monitored and supported, particularly during the first year or so when weight loss is relatively rapid. If bone health is affected, this can be managed and treated.

Source: The Epoch Times